



Verona Pharma plc

Current share price 3.88p
 Market cap £8.34m
 Number of Shares 215.26m
 Ticker VRP
 Broker/Nomad
 WH Ireland Limited

Financial PR
 Bishopsgate Communications


Recent Announcements

- 31 Mar. 09 Notice of Interest in the Company
- 25 Mar. 09 Preliminary Results 2008
- 28 Jan. 09 Approval to Start Clinical Trials of RPL554

Key Personnel

Clive Page - Chairman
 Michael Walker - CEO
 Lui Franciosi - COO
 Danny Lowe - CFO
 Claire Poll - Corporate Director
 Trevor Jones - Non-Exec. Director
 Stuart Bottomley - Non-Exec. Director

Share Price Chart



Contact Details

Verona Pharma Plc
 Suite 21 - Alpha House
 100 Borough High Street
 London SE1 1LB
 Tel: +44 (0)20 7863 3300
 Fax: +44 (0)20 7863 3314

Media Enquiries

Bishopsgate Communications Ltd
 E: veronapharma@bishopsgatecommunications.com
 T: 020 7562 3350

Overview

Verona Pharma plc is a life sciences company dedicated to the research, discovery and development of new therapeutic drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hayfever) and chronic obstructive pulmonary disease (COPD) (smokers' disease), as well as chronic inflammatory diseases.

On 19 September 2006, Verona Pharma plc had its name changed from Isis Resources plc (Isis) after it had successfully acquired the entire issued share capital of Rhinopharma Limited, a drug discovery company founded in Vancouver, Canada. Isis was incorporated on 24 February 2005 in England and Wales, and admitted to trading on AIM on 23 March 2005

Current and recent activity

The Company has three potential drug treatments under development aimed at the respiratory and inflammatory diseases markets:

RPL554: Currently in Phase I/IIa clinical trial as a new treatment for asthma by relaxing airways (bronchodilator) and reducing inflammation - a reliever and controller that originates from the creative mind of Sir David Jack. This drug is a potential replacement for current asthma therapy.

NAIPs: Novel anti-inflammatory drugs based upon molecules from biological sources - using natural sugars from marine creatures to combat inflammation.

Cough: New ways to treat cough - a major unmet medical need. We have a new approach for this neglected condition.

Outlook

R&D Pipeline for Continued Growth: Leverage the experience and network of the Company's board and management team to build a pipeline of new potential drug candidates for the treatment of respiratory and inflammatory diseases.

Targeting significant markets: Focus on markets that offer significant potential. There is currently no ideal drug treatment for asthma, rhinitis and COPD, each disease represents a multimillion dollar market.

Rapid Route to Market: Pursue drug development programmes with a relatively rapid and low cost route to market, such as allergic rhinitis.

Early Crucial Milestones: Define early crucial milestones for the Company's programmes so that any scientific or other issues can be identified before a significant investment is made.

Virtual R&D Model: Outsource much of the Company's research and development, thereby reducing the need for a large specialized workforce and investment in physical infrastructure.

Commercialization through strategic partnerships and business associations: Enter into outlicensing or other arrangements with commercial development partners at the clinical proof of concept or earlier, with the intention of accelerating commercialization and increasing the chances of success.

For more information about the company and its projects, please view Prof. Michael Walker's 'Trading Places' interview done on 20. Feb. 2009, located at: <http://www.veronapharma.com/s/Home.asp>